RxDoctor Payments Data

Heather Roy

Nurse Practitioner · Fort Wayne, INNPI 1437702511

Payments from drug & device makers

$8,333in general payments, 2019–2025

Across 428 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Amgen$1K
  • Johnson & Johnson$881
  • Mallinckrodt Hospital Products Inc.$597
  • GSK$557
  • Novartis$445
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$7,72093%
  • Education$6137%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,333 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$161,891
Medicare patients
258
Services billed
22,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept91$700,095
Humira(Cf) PenAdalimumab92$640,738
Orencia ClickjectAbatacept49$278,791
Cimzia (2 Pack)Certolizumab Pegol37$207,381
XeljanzTofacitinib Citrate25$164,979
Cosentyx Sensoready (2 Pens)Secukinumab18$153,489
RinvoqUpadacitinib23$152,941
Cosentyx Unoready PenSecukinumab19$142,964
Taltz AutoinjectorIxekizumab14$136,097
BenlystaBelimumab22$104,944
Xeljanz XrTofacitinib Citrate15$83,850
Hydroxychloroquine Sulfate354$13,066
Leflunomide161$9,257
MethotrexateMethotrexate Sodium306$6,132
Gabapentin116$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$414$207,38137 claims
PfizerXeljanz$432$164,97925 claims
AbbVieRinvoq$2,826$152,94123 claims
GSKBenlysta$557$104,94422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →